Therefore, our 4 mRNA signatures (MLLT3, CEBPA, HIST2H3C and AFF1) may offer an approach for risk assessment and predicting the prognosis in pediatric and adolescent CN-AML patients. The gene discussed is CEBPA; the disease is acute myeloid leukemia.